# Knowledge and Practices of ADR Reporting in LMICs

> **NCT04301219** · — · COMPLETED · sponsor: **Getz Pharma** · enrollment: 1500 (actual)

## Conditions studied

- Adverse Reaction

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04301219
- **Lead sponsor:** Getz Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-01
- **Primary completion:** 2018-03-01
- **Final completion:** 2018-12-01
- **Target enrollment:** 1500 (ACTUAL)
- **Last updated:** 2020-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04301219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04301219, "Knowledge and Practices of ADR Reporting in LMICs". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04301219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*